Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dimethyl fumarate associated lymphopenia in clinical practice.

Literature DB >> 25432948

Dimethyl fumarate associated lymphopenia in clinical practice.

Erin E Longbrake¹, Anne H Cross².

Abstract

Entities: CellLine Chemical Disease Gene Species

Keywords: Dimethyl fumarate; lymphopenia; multiple sclerosis

Mesh：

Substances：

Year: 2014 PMID： 25432948 PMCID： PMC4426020 DOI： 10.1177/1352458514559299

Source DB: PubMed Journal: Mult Scler ISSN： 1352-4585 Impact factor: 6.312

× No keyword cloud information.

5 in total

1. PML in a patient treated with dimethyl fumarate from a compounding pharmacy.

Authors: Bob W van Oosten; Joep Killestein; Frederik Barkhof; Chris H Polman; Mike P Wattjes
Journal: N Engl J Med Date: 2013-04-25 Impact factor: 91.245

2. PML in a patient treated with fumaric acid.

Authors: Ummehan Ermis; Joachim Weis; Jörg B Schulz
Journal: N Engl J Med Date: 2013-04-25 Impact factor: 91.245

3. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Authors: Robert J Fox; David H Miller; J Theodore Phillips; Michael Hutchinson; Eva Havrdova; Mariko Kita; Minhua Yang; Kartik Raghupathi; Mark Novas; Marianne T Sweetser; Vissia Viglietta; Katherine T Dawson
Journal: N Engl J Med Date: 2012-09-20 Impact factor: 91.245

4. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Authors: Ralf Gold; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Gavin Giovannoni; Krzysztof Selmaj; Carlo Tornatore; Marianne T Sweetser; Minhua Yang; Sarah I Sheikh; Katherine T Dawson
Journal: N Engl J Med Date: 2012-09-20 Impact factor: 91.245

Review 5. Progressive multifocal leukoencephalopathy and idiopathic CD4 lymphocytopenia.

Authors: Manuel Delgado-Alvarado; María José Sedano; Vicente González-Quintanilla; Enrique Marco de Lucas; José Miguel Polo; José Berciano
Journal: J Neurol Sci Date: 2013-03-05 Impact factor: 3.181

5 in total

20 in total

Review 1. Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy.

Authors: Ralf A Linker; Aiden Haghikia
Journal: Ther Adv Chronic Dis Date: 2016-06-10 Impact factor: 5.091

Review 2. [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Authors: L Klotz; A Berthele; W Brück; A Chan; P Flachenecker; R Gold; A Haghikia; K Hellwig; B Hemmer; R Hohlfeld; T Korn; T Kümpfel; M Lang; V Limmroth; R A Linker; U Meier; S G Meuth; F Paul; A Salmen; M Stangel; B Tackenberg; H Tumani; C Warnke; M S Weber; T Ziemssen; F Zipp; H Wiendl
Journal: Nervenarzt Date: 2016-06 Impact factor: 1.214

3. Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study.

Authors: Massimiliano Mirabella; Luca Prosperini; Matteo Lucchini; Laura Boffa; Giovanna Borriello; Maria Chiara Buscarinu; Diego Centonze; Antonio Cortese; Chiara De Fino; Laura De Giglio; Giorgia Elia; Roberta Fantozzi; Elisabetta Ferraro; Ada Francia; Simona Galgani; Claudio Gasperini; Shalom Haggiag; Doriana Landi; Girolama Alessandra Marfia; Enrico Millefiorini; Fabrizia Monteleone; Viviana Nociti; Marco Salvetti; Eleonora Sgarlata; Carlo Pozzilli
Journal: CNS Drugs Date: 2018-10 Impact factor: 5.749

Dimethyl fumarate associated lymphopenia in clinical practice.

1. PML in a patient treated with dimethyl fumarate from a compounding pharmacy.

2. PML in a patient treated with fumaric acid.

3. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

4. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Review 5. Progressive multifocal leukoencephalopathy and idiopathic CD4 lymphocytopenia.

Review 1. Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy.

Review 2. [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

3. Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study.

4. Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis.

Review 5. Managing Risks with Immune Therapies in Multiple Sclerosis.

6. Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.

Review 7. Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate.

8. Multiple Sclerosis Medications in the VHA: Delivering Specialty, High-Cost, Pharmacy Care in a National System.

Review 9. Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis.

10. Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate.